AZ preps for US filing of kidney disease anaemia drugAstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia Share XAZ preps for US filing of kidney disease anaemia drughttps://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/
Astellas cuts $795m deal with Pandion for type 1 diabetes drugsAstellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from Share XAstellas cuts $795m deal with Pandion for type 1 diabetes drugshttps://pharmaphorum.com/news/astellas-biotech-deal-pandion-diabetes/
Astellas gets EU approval for AML drug XospataThe European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia Share XAstellas gets EU approval for AML drug Xospatahttps://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/
Astellas maintains lead over Daiichi Sankyo with CHMP okay for XospataAstellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, Share XAstellas maintains lead over Daiichi Sankyo with CHMP okay for Xospatahttps://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
Astellas gets nod in Japan for roxadustat, ahead of GSK rivalAstellas has its first approval for roxadustat, getting a green light in Japan for the drug as a Share XAstellas gets nod in Japan for roxadustat, ahead of GSK rivalhttps://pharmaphorum.com/news/astellas-gets-nod-in-japan-for-roxadustat-ahead-of-gsk-rival/
FDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallThe FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has Share XFDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallhttps://pharmaphorum.com/news/fda-approves-jjs-prostate-cancer-drug-erleada-in-new-use-as-zytiga-sales-fall/
FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drugThe FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder Share XFDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-astellas-seattle-genetics-bladder-cancer-drug/
Astellas tests gamification ideas with Japanese universitiesAstellas has teamed up with Tokyo University of the Arts and Yokohama City University to create and commercialise Share XAstellas tests gamification ideas with Japanese universitieshttps://pharmaphorum.com/news/astellas-tests-gamification-ideas-with-japanese-universities/
Astellas pushes non-hormonal menopause drug into phase 3Japan’s Astellas has started treating patients in a phase 3 trial of fezolinetant, a non-hormonal drug for menopausal Share XAstellas pushes non-hormonal menopause drug into phase 3https://pharmaphorum.com/news/astellas-pushes-non-hormonal-menopause-drug-into-phase-3/
